- Home
- BDTX
as 11-15-2024 4:00pm EST
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 161.6M | IPO Year: | 2020 |
| Target Price: | $15.50 | AVG Volume (30 days): | 591.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.36 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.09 - $7.66 | Next Earning Date: | 11-05-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Black Diamond Therapeutics Inc. (BDTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Versant Venture Capital VI, L.P. | BDTX | 10% Owner | Aug 28 '24 | Sell | $6.32 | 221,600 | $1,400,556.32 | 3,726,341 |
Latest Black Diamond Therapeutics Inc. News
BDTX Breaking Stock News: Dive into BDTX Ticker-Specific Updates for Smart Investing
Associated Press Finance
12 days ago
Black Diamond: Q3 Earnings Snapshot
Simply Wall St.
12 days ago
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks
GlobeNewswire
12 days ago
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
16 days ago
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
MT Newswires
a month ago
Black Diamond Cuts Programs, Workforce to Save Funding for Prospective Lung Cancer Therapy
GlobeNewswire
a month ago
Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Benzinga
2 months ago
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
MT Newswires
2 months ago
Sector Update: Health Care Stocks Rise Pre-Bell Monday
Compare BDTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BDTX Black Diamond Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.